Worldwide Prayers for an End to Coronavirus Pandemic
14.5.2020 00:01:00 EEST | Business Wire | Press release
In response to the Higher Committee of Human Fraternity (HCHF) calls to pray for humanity today, 14th May, people of all races, colours, ethnicities, and nationalities stood together in an unprecedented event to pray and supplicate to God for an end to the COVID-19 pandemic, and to guide and inspire scientists find a vaccine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005852/en/
An online press conference on Monday to announce the details of the initiative (Photo: AETOSWire)
From the very first moment the HCHF announced its great initiative, the call gained the blessing and support of the two most prominent religious leaders in the world; His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Pope of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all the world.
Judge AbdelSalam, Secretary-General of the HCHF, held an online press conference on Monday, attended by Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis, and Irina Bokova, Former Director General of UNESCO during which he announced the details of the initiative in the presence of local and international media outlets.
Judge Mohamed AbdelSalam stated: “This support for the initiative is clear evidence that we can, especially when addressing common challenges, put aside our disagreements under the banner of our human fraternity. Believing that our common human values is the driving force for the HCHF’s members to announce the call to pray, fast and perform charitable work to rid mankind of this pandemic and its consequences.”
Judge AbdelSalam also announced the launch of the official website of the ‘Pray for Humanity’ initiative (pray.forhumanfraternity.org), which will provide live coverage of the day and will serve as a digital archive for this historic day and future events of the HCHF.
The HCHF was established to implement the humanitarian principles advocated by the Document on Human Fraternity and engage all religious and international organisations in this process to achieve peace, coexistence, global citizenship and human fraternity.
The HCHF consists of a group of influential figures of diverse religious and cultural backgrounds and experts in the fields of Inter-culture communication, interfaith dialogue and social coexistence:
- Cardinal Miguel Ángel Ayuso Guixot, President of the Pontifical Council for Interreligious Dialogue of the Holy See,
- Professor Mohamed Hussein Mahrasawi, President of Al-Azhar University,
- Judge Mohamed Mahmoud AbdelSalam, Former Advisor to the Grand Imam of Al-Azhar and the Secretary-General of the Committee,
- Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation,
- Irina Bokova, Former Director General of UNESCO,
- H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture in Abu Dhabi,
- Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis,
- Dr. Sultan Al Remeithi, Secretary-General of the Muslim Council of Elders,
- Leymah Gbowee, a Liberian peace activist and Nobel Peace Laureate,
- Yasser Hareb, Emirati Writer and TV Presenter
- Father Professor Dr. Ioan Sauca, the Secretary-General of the World Council of Churches.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005852/en/
Contact information
Abeer Mahmoud
abeer@pyramedia.biz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom